Editor's note

This ExpertREACT article was originally published on 25 June 2009. Epidemiological data and pipeline statuses described reflect the state of knowledge at that date.

Chikungunya: re-emerging with global reach

Chikungunya virus (CHIK) is an RNA alphavirus (Togaviridae) first described in East Africa in the early 1950s, spread by Aedes mosquitoes - the same vectors responsible for dengue transmission. Unlike dengue, CHIK infection is rarely fatal but can cause debilitating joint pain, high fever, nausea, rash and fatigue that may be prolonged and recurrent, causing significant morbidity especially during large epidemics. Immunocompromised individuals, the very old and very young, and pregnant women face heightened risk, with evidence that CHIK can be passed transplacentally from mother to foetus. There is currently no specific treatment and no licensed preventative vaccine.

CHIK became of increasing concern following large-scale explosive outbreaks in Indian Ocean islands and India. In La Réunion (France) alone, approximately 35-40% of the population (~260,000 people) were infected, with around 250 deaths (case fatality rate ~1/1,000) concentrated in the over-70 age group. In India in 2006, 1.4 million suspected CHIK cases were reported to national authorities, though when normalised for seroprevalence approximately 148,000 cases were estimated to be laboratory-confirmable CHIK - with investigators estimating around 3,000 excess deaths. The geographic spread to Europe and the Americas via Aedes albopictus was an escalating concern, with imported cases recorded in Italy, France and beyond.

La Réunion Chikungunya outbreak
~260,000
Cases in La Réunion (France); 35-40% of the island's population infected during the 2005-2006 epidemic with approximately 250 deaths

Commercial viability: is a restart justified?

VacZine Analytics' analysis assessed the commercial viability of a Chikungunya vaccine relative to competing priorities. The relatively small number of Western travellers at risk and the self-limiting nature of most CHIK illness in healthy adults presented challenges for premium-priced travel vaccine positioning. However, the large endemic burden in South-East Asia and Africa, the potential for outbreak-driven demand (as experienced with H1N1), and the growing geographic spread suggested that long-term commercial opportunity was meaningful. The analysis concluded that manufacturers should at least reassess whether the Chikungunya vaccine development programmes - some of which had advanced to Phase I in earlier years before being deprioritised - merited re-initiation in the context of growing evidence for endemic spread.